DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
M Sulyok, T Rückle, A Roth, RE Mürbeth… - The Lancet Infectious …, 2017 - thelancet.com
Background A drug for causal (ie, pre-erythrocytic) prophylaxis of Plasmodium falciparum
malaria with prolonged activity would substantially advance malaria control. DSM265 is an …
malaria with prolonged activity would substantially advance malaria control. DSM265 is an …
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial …
SC Murphy, ER Duke, KJ Shipman… - The Journal of …, 2018 - academic.oup.com
Background DSM265 is a selective inhibitor of Plasmodium dihydroorotate dehydrogenase
that fully protected against controlled human malarial infection (CHMI) by direct venous …
that fully protected against controlled human malarial infection (CHMI) by direct venous …
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo …
JL van der Plas, VP Kuiper, WM Bagchus… - The Lancet Infectious …, 2023 - thelancet.com
Background Cabamiquine is a novel antimalarial that inhibits Plasmodium falciparum
translation elongation factor 2. We investigated the causal chemoprophylactic activity and …
translation elongation factor 2. We investigated the causal chemoprophylactic activity and …
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or …
A Llanos-Cuentas, M Casapia… - The Lancet Infectious …, 2018 - thelancet.com
Background DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate
dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against …
dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against …
Malaria chemoprophylaxis: when should we use it and what are the options?
E Petersen - Expert Review of Anti-infective Therapy, 2004 - Taylor & Francis
Malaria chemoprophylaxis concerns prescribing healthy individuals medication for an
infection they have an unknown chance of getting. Sensible use of malaria …
infection they have an unknown chance of getting. Sensible use of malaria …
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
JS McCarthy, J Lotharius, T Rückle… - The Lancet Infectious …, 2017 - thelancet.com
Background DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the …
dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the …
Prolonged Protection Provided by a Single Dose of Atovaquone-Proguanil for the Chemoprophylaxis of Plasmodium falciparum Malaria in a Human Challenge Model
GA Deye, RS Miller, L Miller, CJ Salas… - Clinical Infectious …, 2012 - academic.oup.com
Background. We conducted a randomized, placebo-controlled, double-blind trial to establish
the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly …
the efficacy of atovaquone-proguanil to prevent malaria with the goal of simulating weekly …
The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt …
Abstract Background The majority of Plasmodium falciparum malaria cases in Africa are
treated with the artemisinin combination therapies artemether-lumefantrine (AL) and …
treated with the artemisinin combination therapies artemether-lumefantrine (AL) and …
DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium …
KA Collins, T Rückle, S Elliott, L Marquart… - Antimicrobial Agents …, 2019 - Am Soc Microbiol
ABSTRACT DSM265 is a novel antimalarial drug in clinical development that acts as a
selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous phase 1b …
selective inhibitor of Plasmodium dihydroorotate dehydrogenase. In a previous phase 1b …
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country …
I Sagara, AR Oduro, M Mulenga, Y Dieng, B Ogutu… - Malaria Journal, 2014 - Springer
Background Given increasing rates of resistance to existing therapy, new options for
treatment and prophylaxis of malaria are needed. Methods Two randomised, comparative …
treatment and prophylaxis of malaria are needed. Methods Two randomised, comparative …